GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » FCF Yield %

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) FCF Yield % : -137.10 (As of May. 15, 2024)


View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, NovaBay Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-4.15 Mil, and Market Cap is $3.03 Mil. Therefore, NovaBay Pharmaceuticals's FCF Yield % for today is -137.10%.

The historical rank and industry rank for NovaBay Pharmaceuticals's FCF Yield % or its related term are showing as below:

NBY' s FCF Yield % Range Over the Past 10 Years
Min: -526.87   Med: -36.17   Max: -5.49
Current: -137.1


During the past 13 years, the highest FCF Yield % of NovaBay Pharmaceuticals was -5.49%. The lowest was -526.87%. And the median was -36.17%.

NBY's FCF Yield % is ranked worse than
87.97% of 1554 companies
in the Biotechnology industry
Industry Median: -14.48 vs NBY: -137.10

NovaBay Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -8.48%.


NovaBay Pharmaceuticals FCF Yield % Historical Data

The historical data trend for NovaBay Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals FCF Yield % Chart

NovaBay Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44.45 -16.30 -51.39 -170.50 -181.15

NovaBay Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -121.87 -187.77 -232.82 -49.69 -55.17

Competitive Comparison of NovaBay Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, NovaBay Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBay Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's FCF Yield % falls into.



NovaBay Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

NovaBay Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-4.15 / 2.2909608
=-181.15%

NovaBay Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.316 * 4 / 2.2909608
=-55.17%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovaBay Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


NovaBay Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Executives
Tommy Law officer: Interim CFO 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin officer: President, DERMAdoctor, LLC 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin officer: Chief Product Officer 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall officer: General Counsel 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng director NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov director 2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones officer: CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu director SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu 10 percent owner LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu officer: NEO - Sr Mgr and Controller 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit director 95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng director 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang director 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh officer: Interim CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd 10 percent owner FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000